Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
A decreased prostatic blood flow could be one of the risk factors for overactive bladder/ detrusor hyperactivity and benign prostatic hyperplasia/benign prostatic enlargement. The spontaneously hypertensive rat (SHR) shows a chronic pelvic ischemia and detrusor hyperactivity and hyperplastic morphological abnormalities in the ventral prostate. Chronic treatment with nicorandil, silodosin, hydroxyfasudil and olmesartan improved the pelvic blood flow, bladder dysfunction and prostatic hyperplasia in the SHR. These drugs can ameliorate the progression of bladder dysfunction as well as prostatic hyperplasia through an increase in the pelvic blood flow.
|